1-2 of 2
Adriana Balduzzi
Close
Sort by
Journal Articles

Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study

Clinical Trials & Observations
Peter Bader, Ulrike Pötschger, Jean-Hugues Dalle, Laura M. Moser, Adriana Balduzzi, Marc Ansari, Jochen Buechner, Tayfun Güngör, Marianne Ifversen, Gergely Krivan, Herbert Pichler, Marleen Renard, Raquel Staciuk, Petr Sedlacek, Jerry Stein, Jan Robert Heusel, Tony Truong, Jacek Wachowiak, Akif Yesilipek, Franco Locatelli, Christina Peters
Journal: Blood Advances
Blood Adv (2024) 8 (2): 416–428.
https://doi.org/10.1182/bloodadvances.2023010591
Published: 2024
Includes: Supplemental data
Journal Articles

More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling

Peter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, Jean-Hugues Dalle, Ann E. Woolfrey, Merav Bar, Michael R. Verneris, Michael J. Borowitz, Nirali N. Shah, Nathan Gossai, Peter J. Shaw, Allen R. Chen, Kirk R. Schultz, Hermann Kreyenberg, Lucia Di Maio, Gianni Cazzaniga, Cornelia Eckert, Vincent H. J. van der Velden, Rosemary Sutton, Arjan Lankester, Christina Peters, Thomas E. Klingebiel, Andre M. Willasch, Stephan A. Grupp, Michael A. Pulsipher
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3393–3405.
https://doi.org/10.1182/bloodadvances.2019000449
Published: 2019
Includes: Supplemental data